| Name | PD-1/PD-L1-IN-23 |
|---|---|
| Synonyms |
D-Serine, N-[[2-(2,1,3-benzoxadiazol-5-ylmethoxy)-4-[(2-bromo[1,1'-biphenyl]-3-yl)methoxy]-5-chlorophenyl]methyl]-, ethyl ester, hydrochloride (1:1)
Ethyl (2-(benzo[c][1,2,5]oxadiazol-5-ylmethoxy)-4-((2-bromo-[1,1'-biphenyl]-3-yl)methoxy)-5-chlorobenzyl)-D-serinate hydrochloride |
| Description | PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice[1]. |
|---|---|
| Related Catalog | |
| Target |
PD-1/PD-L1[1] |
| References |
| Molecular Formula | C32H30BrCl2N3O6 |
|---|---|
| Molecular Weight | 703.41 |